Filter Results:
- Full text PDF available (1)
Publication Year
1981
2006
- This year (0)
- Last 5 years (0)
- Last 10 years (0)
Publication Type
Co-author
Journals and Conferences
Organism
Learn More
- L L Gustafsson, William F. Ebling, Eiji Osaki, Donald R. Stanski
- Anesthesiology
- 1996
BACKGROUND
In contrast to that of inhalational anesthetics, quantitation of anesthetic depth for intravenous agents has not been well defined. In this study, using rodents, the relationship between… (More)
- Suvendra N. Dutta, Yukihiro Matsumoto, William F. Ebling
- Journal of pharmaceutical sciences
- 1997
- Ashu Sharma, William F. Ebling, William J. Jusko
- Journal of pharmaceutical sciences
- 1998
A precursor-dependent model of indirect pharmacodynamic response which can describe tolerance and rebound was characterized in terms of the effects of changes in the fundamental properties of the… (More)
- D. Russell Wada, Sven Björkman, William F. Ebling, Hideyoshi Harashima, Sandra R. Harapat, Donald R. Stanski
- Anesthesiology
- 1997
BACKGROUND
Understanding the influence of physiological variables on thiopental pharmacokinetics would enhance the scientific basis for the clinical usage of this anesthetic.
METHODS
A… (More)
- William F. Ebling, William J. Jusko
- Journal of Pharmacokinetics and Biopharmaceutics
- 1986
Methods based on moment analysis are described which permit the calculation of the fundamental parameters of reversible drug/metabolite systems. These parameters include the four essential clearances… (More)
- William F. Ebling, D. Russell Wada, Donald R. Stanski
- Journal of Pharmacokinetics and Biopharmaceutics
- 1994
Physiologically based pharmacokinetic modeling procedures employ anatomical tissue weight, blood flow, and steady tissue/blood partition data, often obtained from different sources, to construct a… (More)
- Jeffrey S. Barrett, Jerry Yu, +8 authors Henry J. Pieniaszek
- Biopharmaceutics & drug disposition
- 1999
The disposition of XV459, a potent, selective GP IIb/IIIa antagonist, has been examined following intravenous administration of XP280, the benzenesulphonate salt, and 3H-SA202, the trifluroacetic… (More)
- Craig Laforce, Stanley J Szefler, Mark F. Miller, William F. Ebling, Mathew Brenner
- The Journal of allergy and clinical immunology
- 1983
Methylprednisolone elimination is reduced in the presence of treatment with troleandomycin (TAO), a macrolide antibiotic. To assess whether a similar interaction occurs with a more commonly used and… (More)
- Suvendra N. Dutta, Yukihiro Matsumoto, N U Gothgen, William F. Ebling
- Journal of pharmaceutical sciences
- 1997
Propofol is a unique highly lipid-soluble anesthetic that is formulated in a fat emulsion (Diprivan) for intravenous (i.v.) use. It has the desirable properties of rapid onset and offset of effect… (More)
- Stanley J Szefler, William F. Ebling, John W. Georgitis, William J. Jusko
- European Journal of Clinical Pharmacology
- 1986
The disposition and plasma binding of methylprednisolone were examined in seven normal volunteers following the administration of 5, 20 and 40 mg of intravenous methylprednisolone sodium succinate.… (More)